美股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

2倍做多NVO ETF-Defiance

17.59

+2.8919.66%

盘后：19.191.60+9.10%19:59 EST

成交量：101.75万

成交额：1,713.04万

市值：5,097.76万

市盈率：- -

高：17.61

开：16.70

低：16.36

收：14.70

52周最高：105.60

52周最低：14.59

股本：289.81万

流通股本：279.81万

量比：0.62

换手率：36.36%

股息：- -

股息率：- -

净资产收益率：--

总资产收益率：--

市净率：--

市盈率(LYR):- -

数据加载中...

总览公司新闻资讯公告

概念

no data

没有相关数据

资金流向

资金流入：

资金流出：

新闻资讯

同为减肥药巨头，诺和诺德市值不及礼来的1/5……

诺和诺德联合减重疗法临床3期结果积极；辉瑞超长效GLP-1受体激动剂将启动3期试验…… | TIDES周报

行业研究 | 2026 年 FDA 多肽新药展望：6 款潜力产品引领行业破局

诺和诺德市值蒸发4500亿美元，遭遇六个月来最差单周表现

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/NVOX"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"NVOX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NVOX\",,,,,undefined,":{"symbol":"NVOX","market":"US","secType":"STK","nameCN":"2倍做多NVO ETF-Defiance","latestPrice":17.59,"timestamp":1770411600000,"preClose":14.7,"halted":0,"volume":1017450,"hourTrading":{"tag":"盘后","latestPrice":19.19,"preClose":17.59,"latestTime":"19:59 EST","volume":60982,"amount":1153960.0371,"timestamp":1770425948484,"change":1.6,"changeRate":0.090961,"amplitude":0.127914},"delay":0,"changeRate":0.19659863945578235,"floatShares":2798101,"shares":2898100,"eps":0,"marketStatus":"休市中","change":2.89,"latestTime":"02-06 16:00:00 EST","open":16.7,"high":17.61,"low":16.36,"amount":17130440.38545,"amplitude":0.085034,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":2,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1770627600000},"marketStatusCode":7,"adr":0,"exchange":"ARCA","adjPreClose":14.7,"sharesOutstanding":2818101,"nav":14.67,"aum":41341541.67,"bidAskSpread":0,"preHourTrading":{"tag":"盘前","latestPrice":16.73,"preClose":14.7,"latestTime":"09:29 EST","volume":114049,"amount":1878015.002162,"timestamp":1770388174508,"change":2.03,"changeRate":0.138095,"amplitude":0.034694},"postHourTrading":{"tag":"盘后","latestPrice":19.19,"preClose":17.59,"latestTime":"19:59 EST","volume":60982,"amount":1153960.0371,"timestamp":1770425948484,"change":1.6,"changeRate":0.090961,"amplitude":0.127914},"volumeRatio":0.6174747072051386,"impliedVol":0.8418,"impliedVolPercentile":0.524},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NVOX\",,,,,undefined,":{"symbol":"NVOX","floatShares":2798101,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.6174747072051386,"shares":2898100,"dividePrice":0,"high":17.61,"amplitude":0.085034,"preClose":14.7,"low":16.36,"week52Low":14.5902,"pbRate":"--","week52High":105.6,"institutionHeld":0,"latestPrice":17.59,"eps":0,"divideRate":0,"volume":1017450,"delay":0,"ttmEps":0,"open":16.7,"prevYearClose":21.89,"prevWeekClose":28.89,"prevMonthClose":28.89,"prevQuarterClose":21.89,"fiveDayClose":28.89,"twentyDayClose":27.54,"sixtyDayClose":18.72},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NVOX\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-12-09","symbol":"NVOX","defaultRemindTime":1765290600000,"type":"split","dateTimestamp":1765256400000,"forFactor":8,"toFactor":1,"ratio":8}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NVOX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"NVOX\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NVOX\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2609515522","title":"同为减肥药巨头，诺和诺德市值不及礼来的1/5……","url":"https://stock-news.laohu8.com/highlight/detail?id=2609515522","media":"医药财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609515522?lang=zh_cn&edition=fundamental","pubTime":"2026-02-08 08:58","pubTimestamp":1770512301,"startTime":"0","endTime":"0","summary":"凭借减肥药风光无限的丹麦巨头诺和诺德，其市值竟然仅是美国竞争对手礼来的约五分之一。礼来预测今年营收将增长约25%，而诺和诺德却警告称销售额可能下降5%至13%。诺和诺德虽然率先推出了口服GLP-1药物Wegovy，但礼来预计将在2026年第二季度获得其口服药物orforglipron的批准。更令人担忧的是，诺和诺德在美国市场的份额正在被礼来侵蚀。这一协议预计将影响两家公司的收入，但对诺和诺德的冲击更为明显。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260208092058a4899dde&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260208092058a4899dde&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0225283273.USD","LU0316494557.USD","LU0672654240.SGD","LLYZ","LU2063271972.USD","BK4533","IE00BZ1G4Q59.USD","LU1023059063.AUD","LU2028103732.USD","IE00BFTCPJ56.SGD","LU0471298777.SGD","LU2471134952.CNY","LU0158827948.USD","LU0109391861.USD","LU2111349929.HKD","NVO","LU2237443465.HKD","LU2468319806.SGD","LU2756315318.SGD","LU1868836757.USD","LU1291159041.SGD","LU0820561909.HKD","LU1989771016.USD","LU0820562030.AUD","LU0353189680.USD","LU2168564065.EUR","LU2361044865.SGD","LU2471134879.HKD","LU2552382215.SGD","LU0471298694.HKD","LU0354030438.USD","LU0198837287.USD","LU0964807845.USD","SGXZ57979304.SGD","LU0096364046.USD","LU0354030511.USD","LU0097036916.USD","LU2264538146.SGD","BK4581","LU2168564495.EUR","LU2237443895.HKD","SGXZ51526630.SGD","LU1868836914.USD","LU1804176565.USD","LU2112291526.USD","SG9999014914.USD","LU0323591593.USD","LU2750360641.GBP","LU0256863902.USD","SGXZ99366536.SGD","LU2236285917.USD","IE00BK4W5M84.HKD","LU0689472784.USD","LU0058720904.USD","LU2324357040.USD","IE00BKDWB100.SGD","LU1988902786.USD","LU1035775433.USD","SG9999001176.SGD","LU0823434740.USD","IE00B2B36J28.USD","LU1629891620.HKD","LU2168563687.JPY","LU2237443549.SGD","IE0009355771.USD","BK4588","LU1323610961.USD","BK4585","IE00B1BXHZ80.USD","IE00BWXC8680.SGD","LU2417539215.USD","LU2491050071.SGD","IE0004445239.USD","NVOX","SG9999014898.SGD","LU1061106388.HKD","LU2089284900.SGD","IE00B4R5TH58.HKD","LU0122379950.USD","LU0823416689.USD","LU1720051017.SGD","SG9999015945.SGD","LU0289739699.SGD","LU1623119135.USD","LU2211815571.USD","LU2213496289.HKD","SG9999015952.SGD","IE00BN29S564.USD","LU2552382058.USD","IE0004445015.USD","LU1814569148.SGD","LU1868837300.USD","LU2087625088.SGD","LU1069344957.HKD","SG9999015986.USD","LU2023250504.SGD","LU1720051108.HKD","BK4007","LU1551013342.USD","BK4599","LU1548497426.USD","LU2602419157.SGD","LU0238689110.USD","IE0002141913.USD","IE00B1XK9C88.USD","SG9999001176.USD","LU2237443382.USD","SG9999017495.SGD","LU0787776722.HKD","LU0353189763.USD","LU0417517546.SGD","LU2108987350.USD","LU1551013425.SGD","LU0256863811.USD","BK4534","LU2456880835.USD","LU0203201768.USD","LU1093756325.SGD","LU2023251221.USD","LU0210536198.USD","LU2271345857.HKD","SG9999013999.USD","SG9999018865.SGD","LU2089984988.USD","LU1232071149.USD","LU1093756168.USD","LU0683600562.USD","LU0385154629.USD","LU2750360997.AUD","LU2471134796.USD","LU2361044949.HKD","LU0786609619.USD","LU0106261372.USD","LU1868837136.USD","LU2089283258.USD","LU0320765992.SGD","LU2237443622.USD","LU0889565916.HKD","LU0114720955.EUR","LU1983299246.USD","LU2361045086.USD","SG9999014906.USD","IE00BJJMRZ35.SGD","LU1267930730.SGD","LU2168564149.EUR","SG9999015978.USD","LU2461242641.AUD","LU0943347566.SGD","LU0203202063.USD","NVOH","LU1127390331.HKD","LU0006306889.USD","LU2896262040.SGD","LU0820561818.USD","IE00BJT1NW94.SGD","LU0079474960.USD","LU2746668461.USD","LU2746668974.SGD","IE00B4JS1V06.HKD","LU0466842654.USD","LU2471134523.USD","LU0234572021.USD","LU2357305700.SGD","LU0154236417.USD","LU1280957306.USD","SGXZ31699556.SGD","LU1712237335.SGD","LU2360106947.USD","LU0882574139.USD","LU2552382132.HKD","IE00BK4W5L77.USD","LU0061475181.USD","LU2237443978.SGD","BK4516","LU2491049909.HKD","LU1057294990.SGD","LU2237438978.USD","IE00BJJMRY28.SGD","LU0882574055.USD","LU1145028129.USD","GB00BDT5M118.USD","LU0094547139.USD","BK4532","IE00BKPKM429.USD","ELIL","LU2023250330.USD","LLY","SG9999014880.SGD","IE00BFSS7M15.SGD","LU2168564222.USD","SG9999018857.SGD","IE00B7KXQ091.USD","IE00BJLML261.HKD","ELIS","SGXZ81514606.USD","IE00BKVL7J92.USD","LU0708995401.HKD","LU2491050154.USD","IE00B775H168.HKD","LU0456855351.SGD","LU1974910355.USD","LU2462157665.USD","IE0005OL40V9.USD","LU1064131342.USD","LU2106854487.HKD","LU0158827781.USD","IE00BJJMRX11.SGD","LU0432979614.USD","LU1868836591.USD","IE00BFSS8Q28.SGD","LU2265009873.SGD","LU1366192091.USD","LU0109394709.USD","LU2756315664.SGD","LLYX","LU0320765059.SGD","LU0640476718.USD","LU1917777945.USD","LU0266013472.USD","LU0823434583.USD"],"gpt_icon":0},{"id":"2609521049","title":"诺和诺德联合减重疗法临床3期结果积极；辉瑞超长效GLP-1受体激动剂将启动3期试验…… | TIDES周报","url":"https://stock-news.laohu8.com/highlight/detail?id=2609521049","media":"药明康德","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609521049?lang=zh_cn&edition=fundamental","pubTime":"2026-02-08 07:31","pubTimestamp":1770507063,"startTime":"0","endTime":"0","summary":"CagriSema：公布3期临床试验数据诺和诺德公布全球REIMAGINE临床试验项目中REIMAGINE 2临床3期研究的主要结果。PF'3944是一款超长效、完全偏向性的GLP-1受体激动剂，是辉瑞通过近期收购Metsera所获得的管线，目前正被开发为每周单药治疗及每月治疗方案。截至第28周，PF'3944保持了与GLP-1 RA类药物一致的良好耐受性和有利的安全性特征。目前，MT1013正在中国开展针对该患者群体的3期临床研究，已入组超50%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260208073656a4896362&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260208073656a4896362&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0321505439.SGD","NVOH","LU0321505868.SGD","LU0154236417.USD","LU1066053197.SGD","BK4588","BK4144","LU0234572021.USD","BK4533","BK4534","LU1894683348.USD","PFE","SG9999013999.USD","LU1093756325.SGD","SG9999003800.SGD","LU1894683264.USD","NVO","LU1057294990.SGD","IE00BLSP4239.USD","LU0289739699.SGD","IE00BLSP4452.SGD","LU0306807586.USD","IE00BBT3K403.USD","LU1093756168.USD","LU0456855351.SGD","BK4599","LU0225284248.USD","BK4581","LU0868494617.USD","SG9999011175.SGD","SG9999001176.USD","IE00BKVL7J92.USD","IE0002270589.USD","BK4592","IE00B19Z3581.USD","BK4590","SG9999002232.USD","LU0122379950.USD","LU0225771236.USD","BK4532","SG9999001176.SGD","NVOX","BK4550","IE00BZ1G4Q59.USD","LU1066051498.USD","IE00B19Z3B42.SGD","SG9999002224.SGD","BK4568","LU0170899867.USD","LU1023059063.AUD","LU0058720904.USD","LU0306806265.USD","LU0985481810.HKD","BK4585","LU1883839398.USD","IE000M9KFDE8.USD","SGXZ57979304.SGD","BK4007"],"gpt_icon":0},{"id":"2609543571","title":"行业研究 | 2026 年 FDA 多肽新药展望：6 款潜力产品引领行业破局","url":"https://stock-news.laohu8.com/highlight/detail?id=2609543571","media":"多肽圈","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609543571?lang=zh_cn&edition=fundamental","pubTime":"2026-02-07 09:00","pubTimestamp":1770426012,"startTime":"0","endTime":"0","summary":"过去一年里，所谓的 “Tide” 军团中仅有四款新药获得 FDA 批准，而其中的主角并非多肽，而是寡核苷酸。该药于 2025 年 9 月获得 FDA 加速批准，用于改善 Barth 综合征患者的肌力，也由此成为这一病种的首个获批治疗选择。2025 年更像是一个多肽药物的“调整期”，而非真正的高光时刻。从 FDA 已披露的新药审评进度来看，一批多肽类 NCE 以及以多肽为关键驱动的产品形态，已经接近关键节点。FDA已受理其NDA并给出2026年8月28日的PDUFA目标日。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260207093559a6dd821e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260207093559a6dd821e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4116","IE00BZ1G4Q59.USD","LU1093756168.USD","BK4585","BK4007","BK4532","LU0154236417.USD","BK4023","BK4588","IE00BKVL7J92.USD","NVOH","LU1093756325.SGD","BK4599","NVOX","NVO"],"gpt_icon":1},{"id":"2609513560","title":"诺和诺德市值蒸发4500亿美元，遭遇六个月来最差单周表现","url":"https://stock-news.laohu8.com/highlight/detail?id=2609513560","media":"新浪财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609513560?lang=zh_cn&edition=fundamental","pubTime":"2026-02-07 01:14","pubTimestamp":1770398053,"startTime":"0","endTime":"0","summary":"尽管周五股价小幅反弹，该股仍难逃六个月来的最差单周表现。自 2024 年 6 月市值触及 6590 亿美元峰值后，诺和诺德多年来的惊人涨幅化为乌有。诺和诺德将欧唐静的有效成分司美格鲁肽重新研发，打造出专用于减肥的维格卫，并于 2021 年 6 月获得美国监管机构批准上市，推动公司股价一路飙升。原本，维格卫口服版的上市被视为诺和诺德巩固竞争优势的契机，公司股价 1 月的反弹也创下五个月来最大涨幅。诺和诺德发布声明时，其股价盘中跌幅已达 10%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260207011701a4857ae1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260207011701a4857ae1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4599","IE00BZ1G4Q59.USD","BK4532","NVOX","LU0154236417.USD","NVO","BK4007","LU1093756325.SGD","BK4585","LU1093756168.USD","BK4588","NVOH","IE00BKVL7J92.USD"],"gpt_icon":1}],"pageSize":4,"totalPage":12,"pageCount":1,"totalSize":47,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/NVOX\",params:#limit:6,delay:false,,,undefined,":[]}}